Research
What Is BPC-157? A Complete Research Overview
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide composed of 15 amino acids, originally isolated as a fragment of a larger protein found in human gastric juice. It has become one of the most widely studied research peptides in preclinical science, with a broad body of literature exploring its potential roles in tissue repair, inflammation modulation, angiogenesis, and neuroprotection.
This article provides a comprehensive overview of BPC-157 for researchers, covering its molecular structure, proposed mechanisms of action, preclinical research landscape, regulatory status, and considerations for laboratory use.
What Does BPC-157 Stand For?
BPC-157 stands for Body Protection Compound 157. The “BPC” designation refers to its origin as a fragment derived from the body protection compound (BPC), a protein naturally occurring in human gastric juice. The “157” refers to its position as a specific 15-amino-acid sequence (pentadecapeptide) within that larger protein.
The full amino acid sequence of BPC-157 is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Molecular Formula: C₆₂H₉₈N₁₆O₂₂
- Molecular Weight: ~1,419 Da
- CAS Number: 137525-51-0
- Type: Synthetic pentadecapeptide
One of BPC-157’s notable chemical properties is its stability in human gastric juice — an unusual characteristic that has contributed to research interest in its oral bioavailability and gastrointestinal applications.
BPC-157 Mechanism of Action: What Preclinical Research Suggests
Research into BPC-157 has proposed several distinct mechanisms through which it may exert biological effects in preclinical models. These include:
1. Nitric Oxide (NO) System Modulation
BPC-157 has been extensively studied in relation to the nitric oxide signaling pathway. Preclinical literature suggests it may both upregulate and modulate NO synthesis, with observed effects on vascular integrity, blood pressure regulation, and cytoprotective responses in animal models.
2. VEGF Pathway Activation
Multiple studies have reported BPC-157’s interaction with vascular endothelial growth factor (VEGF) signaling, which plays a key role in angiogenesis — the formation of new blood vessels. This mechanism is frequently cited in research exploring BPC-157’s potential role in wound healing and tissue regeneration in preclinical settings.
3. Growth Hormone Receptor Upregulation
A notable finding in tendon fibroblast research is BPC-157’s dose- and time-dependent upregulation of growth hormone receptor expression, which in turn appeared to potentiate growth hormone’s proliferative effects on cells. This has been proposed as a contributing mechanism to the peptide’s observed effects in tendon injury models.
4. Inflammatory Cytokine Modulation
In various preclinical systems, BPC-157 has been associated with reductions in pro-inflammatory cytokines. This anti-inflammatory profile is one reason BPC-157 appears across multiple research domains including musculoskeletal, gastrointestinal, and neurological studies.
5. Cytoprotection
BPC-157’s cytoprotective effects — meaning its observed ability to prevent or reduce cellular damage — have been studied across multiple organ systems in animal models, including the gastrointestinal tract, liver, heart, and central nervous system.
BPC-157 Preclinical Research Landscape
BPC-157 has accumulated a substantial body of preclinical literature since its first description in 1993. As of 2024, published research spans the following domains:
Musculoskeletal Research
BPC-157 has been among the most studied peptides in preclinical orthopedic models. Animal studies have investigated its effects in models of tendon rupture, ligament tears, muscle injuries, and bone fractures. A 2025 systematic review published in The Orthopaedic Journal of Sports Medicine identified 36 preclinical and one clinical study examining BPC-157’s effects in musculoskeletal contexts, with consistent observations of improved structural and functional outcomes in animal injury models.
Gastrointestinal Research
Given its origin in gastric juice, BPC-157’s role in GI mucosal integrity has been a primary research focus since early studies. Preclinical models have examined its effects in inflammatory bowel disease models, gastric ulcer models, and intestinal epithelial repair.
Neurological Research
Emerging preclinical literature has explored BPC-157 in the context of neuroprotection, with proposed mechanisms involving neurotrophic factor modulation and the mitigation of neurological damage in injury and ischemia models.
Cardiovascular Research
Research has studied BPC-157 in preclinical cardiovascular models, focusing on its proposed interactions with endothelial cell function, vascular integrity, and cardiac tissue protection under experimental conditions.
Regulatory Status of BPC-157
Understanding BPC-157’s regulatory status is essential for researchers working in this area.
FDA Status: BPC-157 is not approved by the U.S. Food and Drug Administration (FDA) as a drug, supplement, or food additive. In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance, meaning it cannot be used in compounded pharmaceutical preparations for clinical administration. Products labeled as BPC-157 are marketed as research chemicals for in vitro and laboratory use only.
WADA Status: BPC-157 was temporarily listed under the World Anti-Doping Agency (WADA) Prohibited List in 2022 under the category S0: Non-Approved Substances. As of the most recent update, it is categorized under non-approved substances as it lacks regulatory approval for human use.
Legal Status: BPC-157 is not a DEA-scheduled substance in the United States. Its sale and possession as a research chemical are legal, provided it is clearly labeled and sold for research use only, with no implied or explicit claim of human consumption.
BPC-157 in the Context of Research Chemical Supply
For researchers sourcing BPC-157 for laboratory use, several quality parameters are critical:
Purity: Research-grade BPC-157 should meet a minimum purity threshold of 98%, with premium suppliers achieving 99%+ purity. Purity is typically verified via High-Performance Liquid Chromatography (HPLC).
Identity Verification: Mass spectrometry (MS) analysis confirms that the peptide sequence is correct and matches the known molecular weight and fragmentation pattern of BPC-157.
Certificate of Analysis (COA): Every batch of research-grade BPC-157 should be accompanied by a batch-specific COA documenting HPLC purity percentage, mass spec confirmation, endotoxin levels, and any other relevant quality parameters.
Form: BPC-157 is most stable in lyophilized (freeze-dried) powder form. Reconstitution with bacteriostatic water is standard for most research protocols.
Storage: Lyophilized BPC-157 powder should be stored at -20°C for long-term stability. Once reconstituted, it should be refrigerated at 4°C and used within 2–4 weeks.
Frequently Asked Questions About BPC-157
What is BPC-157 used for in research? BPC-157 is used as a tool compound in preclinical research investigating tissue repair mechanisms, inflammation pathways, gastrointestinal mucosal integrity, angiogenesis, and neuroprotection. All documented research has been conducted in in vitro systems or animal models.
Is BPC-157 the same as body protection compound? BPC-157 is a 15-amino-acid fragment (pentadecapeptide) of the larger body protection compound (BPC) protein found in human gastric juice. It is the active fragment most commonly used in research.
What purity should BPC-157 be for research? For reliable research outcomes, BPC-157 should be sourced at a minimum purity of 98%, verified by HPLC analysis. Leading research chemical suppliers provide 99%+ purity with batch-specific COAs.
Can BPC-157 be used in humans? BPC-157 is not approved for human use by the FDA or any major international regulatory body. It is classified as a research chemical for in vitro and laboratory research purposes only. Bodily introduction of any kind is not permitted under research chemical classifications.
How does BPC-157 differ from TB-500? BPC-157 and TB-500 are both peptides studied for their potential roles in tissue repair, but they have distinct molecular structures and proposed mechanisms. BPC-157 is a 15-amino-acid peptide primarily associated with NO system and VEGF pathway modulation. TB-500 (a fragment of Thymosin Beta-4) is a 7-amino-acid peptide primarily associated with actin-binding and cytoskeletal dynamics. For a detailed comparison, see our BPC-157 vs TB-500 research comparison guide.
All content on Peak Lab Peptides is provided for educational and research purposes only. BPC-157 is intended for in vitro laboratory research use only and is not approved for human or veterinary use, consumption, or medical applications. Researchers should comply with all applicable local, national, and international regulations.